- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00597493
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme
PURPOSE AND OBJECTIVES:
Primary Objective To evaluate the activity of Sorafenib plus protracted, daily temozolomide in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month PFS.
Secondary Objectives To evaluate the safety and toxicity of combination therapy using Sorafenib plus temozolomide; To determine the pharmacokinetics of Sorafenib when combined with temozolomide in patients on and not on concurrent EIAC medications.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
STUDY ACTIVITIES AND POPULATION GROUP:
This is an open-label, non-randomized, single center phase 2 trial. A treatment cycle will consist of 4 weeks of therapy.
Sorafenib will be administered at a set dose of 400 mg (2 x 200 mg tablets) twice daily, without food (at least 1 hour before or 2 hours after eating). Temozolomide will be administered at a set dose of 50 mg/m2 once daily without food (at least 1 hour before or 2 hours after eating).
Thirty-two (32) patients will be enrolled in this single-stage study.
DATA ANALYSIS AND RISK/SAFETY ISSUES:
After 16 patients with recurrent GBM are treated, an interim analysis will be conducted. If 6 or more patients have experienced unacceptable toxicity, accrual of patients in this patient group will be terminated. Otherwise, patient accrual will continue. If 9 or more of the total 32 patients experience unacceptable toxicity, the treatment regimen will be considered to have an unacceptable toxicity profile. The type I and II error rates associated with this testing are 0.053 and 0.053, respectively.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Duke University Health System
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients must have histologically confirmed diagnosis of recurrent/progressive GBM. Recurrence will be distinguished from "pseudoprogression" following XRT/Temodar as outlined in inclusion criteria 4.6 (below). Pts with recurrent disease whose diagnostic pathology confirmed glioblastoma multiforme will not need re-biopsy. Pts with prior low-grade glioma or WHO grade III malignant glioma are eligible if histologic assessment demonstrates transformation to GBM.
- Age > 18 years.
- Pts must be presenting in 1st, 2nd or 3rd relapse. Prior therapy must have included external beam radiotherapy.
Adequate bone marrow, liver and renal function as assessed by following:
- Hemoglobin > 9.0 g/dl
- Absolute neutrophil ct (ANC) > 1,500/mm3
- Platelet ct > 100,000/mm3
- Total bilirubin < 1.5 x ULN
- ALT & AST < 2.5 x ULN ( < 5 x ULN for pts with liver involvement)
- INR < 1.5 or PT/PTT within normal limits (unless on therapeutic anti-coagulation). Pts receiving anti-coagulation treatment with agent such as warfarin or heparin may be allowed to participate. For pts on warfarin, INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by local standard of care, until INR is stable.
- Creatinine < 1.5 x ULN
- An interval of at least 2 weeks between prior surgical resection (1 week for biopsy)& initiation of study regimen;
- An interval of at least 12 weeks from completion of standard, daily XRT, unless 1 of the following occurs: 1) new area of enhancement on MRI imaging that is outside XRT field; 2) biopsy proven recurrent tumor; 3) radiographic evidence of progressive tumor on 2 consecutive scans at least 4 weeks apart.
- An interval of at least 4 weeks from prior chemotherapy (except nitrosoureas which require 6 weeks) unless there is unequivocal evidence of tumor progression and pts has recovered from all anticipated toxicities from prior therapy.
- Karnofsky performance score > 60%.
- Ability to understand and willingness to sign written informed consent. A signed informed consent must be obtained prior to any study specific procedures.
- If sexually active, patients will take contraceptive measures (barrier method of birth control) for duration of treatments and for 3 months following discontinuation of sorafenib & temozolomide.
- Pts who have had prior bevacizumab are eligible however interval of at least 6 weeks must have elapsed since their last dose.
Exclusion Criteria:
- Prior treatment with sorafenib.
- Significant cardiac disease including any of following: a) congestive heart failure > class II NYHA; b) unstable angina (anginal symptoms at rest); c) new onset angina (within last 3 months); d) myocardial infarction within past 6 months; e) cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
- Known severe hypersensitivity to sorafenib or any of excipients or temozolomide.
- Excessive risk of bleeding as defined by stroke within prior 6 months, history of CNS or intraocular bleed, or septic endocarditis.
- Female pts who are pregnant/breast feeding, or adults of reproductive potential not employing effective method of birth control.
- Concurrent severe and/or uncontrolled medical disease that could compromise participation in study such as uncontrolled diabetes, uncontrolled hypertension, active clinically serious infection > CTCAE Grade 2, history of bleeding diathesis or coagulopathy, impairment of GI function or GI disease that may significantly alter absorption of the study regimen (i.e. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow tablets).
- Thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within past 6 months
- Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of 1st dose of study drug.
- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of 1st dose of study drug.
- Serious non-healing wound, ulcer, or bone fracture.
- Major surgery, open biopsy or significant traumatic injury within 4 weeks of 1st study drug.
- Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
- Pt is < 3 years free of another primary malignancy except: if other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is basal cell skin cancer or cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
- Pts unwilling or unable to comply with protocol including ability to swallow whole pills or presence of any malabsorption syndrome.
- Concurrent administration of St. John's Wort.
- Clinically serious infection requiring active intervention (CTCAE grade 2 or greater).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Sorafenib + Temozolomide
Subjects receive 400mg of Sorafenib twice daily and 50mg/m^2 of Temozolomide once daily Subjects continue to receive treatment until any of the following: progressive disease, unacceptable toxicity, non-compliance with study guidelines, withdrawal of patient consent, intercurrent non-cancer-related illness that prevents continuation of therapy or regular follow-up, general or specific changes in a subject's condition which render the patient unacceptable for treatment in the judgement of the investigator, or study closure |
Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib.
Sorafenib will be taken by mouth twice every day.
The dose of sorafenib will be 400 mg (2 x 200mg tablets).
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
6 Month Progression Free Survival (PFS)
Délai: 6 months
|
Percentage of participants surviving six months from the start of study treatment without progression of disease.
PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause.
|
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Safety and Toxicity of Combination
Délai: 16 months
|
Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment.
|
16 months
|
Pharmacokinetics: C-max
Délai: 13 months
|
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose.
C-max refers to maximum plasma concentration.
The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately.
|
13 months
|
Pharmacokinetics: T-max
Délai: 13 months
|
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose.
T-max refers to time to maximum concentration.
The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately.
|
13 months
|
Pharmacokinetics: AUC-24
Délai: 13 months
|
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose.
AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours.
The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately.
|
13 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: David A Reardon, MD, Duke Health
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs par type histologique
- Tumeurs
- Tumeurs, glandulaires et épithéliales
- Attributs de la maladie
- Astrocytome
- Gliome
- Tumeurs, neuroépithéliales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Glioblastome
- Récurrence
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Agents antinéoplasiques, alkylants
- Agents d'alkylation
- Inhibiteurs de protéine kinase
- Témozolomide
- Sorafénib
Autres numéros d'identification d'étude
- Pro00000464
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Sorafenib and Temozolomide
-
hearX GroupUniversity of PretoriaComplété
-
Oregon Health and Science UniversityNational Institute on Aging (NIA)ComplétéDémence | Maladie d'Alzheimer | Membres de la famille | Épuisement professionnel des soignantsÉtats-Unis
-
BayerComplétéCarcinome hépatocellulaireTaïwan
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRecrutementDémence | Déficience cognitive légère | Démence mixte | Démence de type Alzheimer | Déficience cognitive subjective | Démence SénileSuède
-
Cancer Institute and Hospital, Chinese Academy...ComplétéCarcinome hépatocellulaire, radiothérapie, sorafenibChine
-
University of Illinois at Urbana-ChampaignInconnueBlessure de chute | Prévention des chutes | Sécurité antichute
-
Samsung ElectronicsComplétéVieilli | Adultes | Moyen-Âge | Âgé, 80 ans et plusCorée, République de
-
Institut du Cancer de Montpellier - Val d'AurelleUniversity Hospital, Clermont-Ferrand; Laboratoire EPSYLON; Academic resource...Complété
-
Eunice Kennedy Shriver National Institute of Child...Inconnue
-
University of Illinois at ChicagoComplétéPersonnes âgées en bonne santéÉtats-Unis